Pfizer’s U.S. Overhaul Is Paying Off, But Work Is Not Done – CEO Kindler
Executive Summary
Pfizer's "fast-to-market" execution of Lyrica for fibromyalgia is evidence the company is already seeing the benefits of its new U.S. business structure, according to CEO Jeffrey Kindler
You may also be interested in...
Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months
Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months
Pfizer’s Lipitor Patent Claims Rejected by PTO In Initial Reexamination
Pfizer may lose patent protection for its blockbuster cholesterol drug Lipitor (atorvastatin) if the U.S. Patent and Trademark Office stands by an initial decision to reject the claims in the basic patent on the drug